BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2022 Earnings Conference Call February 21, 2023 8:30 AM ET

Company Participants

John Bluth - Investor Relations

Jon Stonehouse - Chief Executive Officer

Anthony Doyle - Chief Financial Officer

Charlie Gayer - Chief Commercial Officer

Helen Thackray - Chief R&D Officer

Conference Call Participants

Jessica Fye - JPMorgan

Tazeen Ahmad - Bank of America

Chris Raymond - Piper Sandler

Liisa Bayko - Evercore ISI

Jon Wolleben - JMP Securities

Ken Cacciatore - Cowen & Company

Justin Kim - Oppenheimer

Brian Abrahams - RBC Capital Markets

Maury Raycroft - Jefferies

Gena Wang - Barclays

Rohit Bhasin - Needham & Co.

Operator

Good morning and welcome to the BioCryst Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead.

John Bluth

Thanks, Andrea. Good morning and welcome to BioCryst’s fourth quarter and year end 2022 corporate update and financial results conference call. Today’s press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we will answer your questions.

Before we begin, please note that today’s conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company’s future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company’s documents filed with the Securities and Exchange Commission, which can be accessed on our website.

I’d now like to turn the call over to Jon Stonehouse.

Jon Stonehouse

Thanks, John. 2022 was another outstanding year for ORLADEYO as we doubled sales in our second full year of launch on top of the fantastic start we had in the first year. This shouldn’t be surprising given the excellent safety, efficacy and once-daily oral profile. We are consistently hearing from patients that ORLADEYO is changing their lives. As you will hear from Charlie, in the U.S., our prescriber base continues to grow both in breadth and depth. In addition, ORLADEYO is already commercially available to HAE patients in 15 countries around the world. The ability of ORLADEYO to deliver meaningful results for patients is driving the steady patient growth we are seeing quarter after quarter. And in 2023, we expect this strong steady demand to continue, leading to the global sales of no less than $320 million.